The University of Lausanne is offering this technology for licensing.

The technology allows fine-tuned analysis of human iNOS functions.

Development Phase :

System currently in use.

Patent Status :

A provisional patent application has been filed on August, 2001. Patent pending.

Patent Attorney :
Mintz & Levin, Boston, USA

Novelty and Benefits :
¨
Regulated and reversible expression system of human iNOS in eukaryotic cells.
¨ The system can easily be convertible into a kit format.

Controlled Synthesis of Inducible Nitric Oxide Synthase (iNOS)

(Reference Number IDF 20/01)

The Technology :

The Cytokine inducible nitric oxide synthase enzyme is responsible for the production of nitric oxide, which has antibacterial and antitumoral functions. Thus iNOS is an important effector in immunity.

Stable expression systems of human iNOS is bacterial and mammalian cells have been described. However, applications of these systems are limited, due to the high level of nitric oxide produced by iNOS, which are toxic.

We propose an expression system allowing regulated and reversible exogenous recombinant expression of human iNOS in eukaryotic cells. This system is particularly suited for fine-tuned analysis of iNOS functions.

Applications :

Expression vector for investigative purposes, such as iNOS effects on gene expression.